ELK GROVE VILLAGE, IL – August 2023 – Orsini Specialty Pharmacy ("Orsini"), a leading independent specialty pharmacy focused on rare diseases and gene...
ELK GROVE VILLAGE, IL – Aug. 23, 2023 – Orsini Specialty Pharmacy ("Orsini"), a leading independent specialty pharmacy focused on rare diseases and...
Orsini Specialty Pharmacy, a leading independent specialty pharmacy focused on rare diseases and gene therapies, announced that BioMarin Pharmaceutical...
The complexities of managing the care of a rare disease patient are tremendous. Several models of care are efficient when optimizing patient care...
Orsini Specialty Pharmacy, a leading independent specialty pharmacy focused on rare diseases and gene therapies, has been selected by Sarepta...
Orsini Specialty Pharmacy, a leader in rare diseases and gene therapies, announced that Aimmune Therapeutics, a Nestle Health Science Company, has...
Recurrent Pericarditis (RP) is a painful auto-inflammatory cardiovascular disease that occurs when patients with acute pericarditis experience one or...
Often when pharmacy benefit manager (PBM) agreements and specialty pharmacy agreements are put into place, no one considers the 1 or 2 percent of the...
Orsini Specialty Pharmacy, a leading independent specialty pharmacy focused on rare diseases and gene therapies, announced that Krystal Biotech has...
Whether it's open, limited, or exclusive, the main goal of all healthcare distribution network systems should be to provide patients access to the...
Orsini is a leading independent national specialty pharmacy accredited by ACHC, JCAHO, URAC, and VIPPS. The services we provide allow patients, physicians, payors, and manufacturers to improve care, simplify processes, and achieve better outcomes.
Orsini Specialty Pharmacy Names Darin DeCarlo Chief Growth Officer
Orsini Specialty Pharmacy Selected to be the Exclusive Specialty Pharmacy Partner for VEOPOZ™ (pozelimab-bbfg), the First and Only Treatment for CHAPLE Disease
Orsini Selected by BioMarin to Dispense ROCTAVIAN™, the First Gene Therapy for the Treatment of Severe Hemophilia A
Optimizing Patient Care Services with Rare Disease Limited Distribution Drugs
Orsini Selected by Sarepta Therapeutics to Dispense ELEVIDYS (delandistrogene moxeparvovec-rokl), the First Gene Therapy to Treat Duchenne Muscular Dystrophy